Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT2 | Q96PD7 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17558284 | 0.87 | DGAT2 (1.00) | DGAT2 | |
| SCHEMBL17571783 | 0.87 | DGAT2 (1.00) | DGAT2 | |
| SCHEMBL17558270 | 0.87 | DGAT2 (1.00) | DGAT2 | |
| SCHEMBL17558219 | 0.84 | DGAT2 (1.00) | DGAT2 | |
| SCHEMBL17558223 | 0.83 | DGAT2 (1.00) | DGAT2 | |
| SCHEMBL17571874 | 0.83 | DGAT2 (1.00) | DGAT2 | |
| SCHEMBL17571776 | 0.83 | DGAT2 (0.74) | DGAT2 | |
| SCHEMBL19376256 | 0.82 | DGAT2 (1.00) | DGAT2 | |
| SCHEMBL20861230 | 0.82 | DGAT2 (0.79) | DGAT2 | |
| SCHEMBL17558299 | 0.82 | DGAT2 (1.00) | DGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3188731-B1 | ISOQUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 | MERCK SHARP & DOHME (US) | 2019-04-03 | — | — | EP | claimed |
| US-9828369-B2 | Isoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 | MERCK SHARPE & DOHME CORP. (US) | 2017-11-28 | — | — | US | claimed |
| US-20170275274-A1 | ISOQUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 | MERCK SHARP & DOHME CORP. (US) | 2017-09-28 | — | — | US | claimed |
| EP-3188731-A1 | ISOQUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 | Merck Sharp & Dohme Corp. (US) | 2017-07-12 | — | — | EP | claimed |
| WO-2016036638-A1 | ISOQUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 | MERCK SHARP & DOHME CORP. (US) | 2016-03-10 | — | — | WO | claimed |
| EP-3188731-B1 | ISOQUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 | MERCK SHARP & DOHME (US) | 2019-04-03 | — | — | EP | disclosed |
| EP-3188731-B1 | ISOQUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 | MERCK SHARP & DOHME (US) | 2019-04-03 | — | — | EP | disclosed |
| US-9828369-B2 | Isoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 | MERCK SHARPE & DOHME CORP. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828369-B2 | Isoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 | MERCK SHARPE & DOHME CORP. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828369-B2 | Isoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 | MERCK SHARPE & DOHME CORP. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170275274-A1 | ISOQUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 | MERCK SHARP & DOHME CORP. (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170275274-A1 | ISOQUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 | MERCK SHARP & DOHME CORP. (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170275274-A1 | ISOQUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 | MERCK SHARP & DOHME CORP. (US) | 2017-09-28 | — | — | US | disclosed |
| WO-2016036638-A1 | ISOQUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 | MERCK SHARP & DOHME CORP. (US) | 2016-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275274-A1 | ISOQUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 | DGAT2, DGAT1, MOGAT2 | DGAT2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.